Skip to main content
Log in

Tenofovir Disoproxil Fumarate

A Review of its Use in the Management of HIV infection

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Tenofovir disoproxil fumarate (tenofovir DF; Viread®), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.

Pharmacological Properties

Tenofovir DF is metabolised to tenofovir diphosphate, which inhibits the activity of HIV reverse transcriptase and terminates the DNA chain. In vitro, the drug demonstrates good inhibitory activity against HIV strains, synergistic or additive activity when combined with certain other antiretroviral drugs, minimal cytotoxicity and no evidence of reduced mitochondrial DNA synthesis.

Reduced susceptibility to tenofovir is associated with the reverse transcriptase mutation K65R. In patients with baseline resistance mutations in clinical trials, the greatest response to tenofovir DF was associated with the M184V mutation and no thymidine analogue-associated mutations. Reduced responses were associated with the L210W or M41L mutations, and a lack of response with the K65R mutation. The emergence of the K65R mutation during clinical trials using more than one class of antiretroviral therapy was specifically associated with tenofovir DF; however, the K65R mutation developed infrequently and was not associated with viral rebound.

The oral bioavailability of tenofovir DF administered without food is 25%. After multiple doses of tenofovir DF 300mg once daily, the median maximum serum concentration of 326 ng/mL at steady state is reached after a median of 2.3 hours. Tenofovir has a median serum terminal elimination half-life of 14.4 hours, and undergoes primarily renal elimination as the unchanged drug. Exposure to tenofovir is increased in patients with moderate-to-severe renal impairment.

Tenofovir does not inhibit cytochrome P450 enzymes, so few drug interactions are expected with drugs metabolised via this route. Coadministration of tenofovir DF with didanosine substantially increases didanosine exposure, coadministration with lopinavir/ritonavir increases tenofovir exposure and coadministration with atazanavir decreases atazanavir exposure.

Therapeutic Efficacy

In two well designed clinical trials in antiretroviral treatment-experienced patients with HIV infection, oral tenofovir DF 300mg once daily in combination with other antiretroviral drugs produced significantly greater time-weighted reductions from baseline in HIV RNA levels than placebo at week 4 and/or 24; these reductions were maintained at week 48 in the placebo cross-over phase of the trials. In the dose-ranging trial, tenofovir DF 75, 150 or 300mg once daily were all more effective than placebo; however, the greatest reduction in viral load at weeks 4, 24 and 48 was produced by tenofovir DF 300mg once daily, which is the approved dosage in patients with HIV infection.

The proportion of antiretroviral therapy-naive patients with HIV infection achieving HIV RNA levels <400 copies/mL was similar with tenofovir DF 300mg once daily and stavudine 40mg twice daily at weeks 48, 96 and 144 in a well designed trial. All patients also received lamivudine 150mg twice daily and efavirenz 600mg once daily. For the primary endpoint, the stratum-weighted lower 95% confidence interval of the difference between tenofovir DF and stavudine at week 48 slightly exceeded (by 0.4) the predefined equivalence criteria (−10.4 vs −10).

In nonblind clinical trials, tenofovir DF 300mg once daily was effective in treating HIV infection when used in a regimen containing antiretroviral therapies from more than one class and as part of a simplified dosage regimen. However, as with other triple NRTI regimens, tenofovir DF with lamivudine plus either didanosine or abacavir showed high rates of suboptimal response and/or early failure.

Tolerability

Oral tenofovir DF 300mg once daily, as part of combination therapy, was generally well tolerated in controlled clinical trials. The tolerability profiles of tenofovir-containing regimens were similar to those of regimens containing placebo or stavudine in controlled clinical trials. Mild-to-moderate gastrointestinal disorders (e.g. nausea, diarrhoea, vomiting and flatulence) were the most commonly reported adverse events.

The frequency of laboratory abnormalities with tenofovir DF was similar to that with placebo and stavudine. However, tenofovir DF was associated with a more favourable serum lipid profile than stavudine.

The risk of adverse events potentially associated with mitochondrial dysfunction with tenofovir DF appears similar to that with placebo and lower than that with stavudine. In clinical trials, the incidence of tenofovir DF-related renal abnormalities was low and similar in frequency between tenofovir DF- and stavudine-containing regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. The Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http://www.AIDSinfo.nih.gov [Accessed 2004 Nov 19]

  2. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the international AIDS society — USA panel. JAMA 2004 Jul 14; 292(2): 251–65

    Article  PubMed  CAS  Google Scholar 

  3. European Agency for the Evaluation of Medicinal Products. Viread (tenofovir disoproxil fumarate): scientific discussion [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Jun 28]

  4. Chapman T, McGavin J, Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63(15): 1597–608

    Article  PubMed  CAS  Google Scholar 

  5. Gilead Sciences Inc. Viread (tenofovir disoproxil fumarate) tablets: US prescribing information [online]. Available from URL: http://www.gilead.com [Accessed 2004 Jul 13]

  6. Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998 Mar; 42(3): 612–7

    PubMed  CAS  Google Scholar 

  7. Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. J Biol Chem 1998 Oct 16; 273(42): 27250–8

    Article  PubMed  CAS  Google Scholar 

  8. Cherrington J, Mulato AS. Adefovir (PMEA) and PMPA show synergistic or additive inhibition of HIV replication in vitro in combination with other anti-HIV agents [abstract no. 41195 plus poster]. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva

  9. Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997 Nov; 36(2): 91–7

    Article  PubMed  CAS  Google Scholar 

  10. Hossain MM, Coull JJ, Drusano GL, et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002 Jul; 55(1): 41–52

    Article  PubMed  CAS  Google Scholar 

  11. Zídek Z, Holý A, Franková D. Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production. Eur J Pharmacol 1997 Jul 23; 331(2–3): 245–52

    Article  PubMed  Google Scholar 

  12. Zídek Z, Holý A, Franková D. Immunomodulatory properties of antiviral acyclic nucleotide analogues: cytokine stimulatory and nitric oxide costimulatory effects. Int J Immunopharmacol 1997 Sep-1997; 19(9–10): 587–97

    Article  PubMed  Google Scholar 

  13. Zídek Z, Franková D, Holý A. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1α) and cytokine (tumour necrosis factor alpha, interleukin-10 [IL-10], IL-1β) production. Antimicrob Agents Chemother 2001 Dec; 45(12): 3381–6

    Article  PubMed  Google Scholar 

  14. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641–8

    Article  PubMed  CAS  Google Scholar 

  15. Birkus G, Hitchcock MJM, Cihlar T, et al. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002 Mar; 46(3): 716–23

    Article  PubMed  CAS  Google Scholar 

  16. Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002; 54: 37–45

    Article  PubMed  CAS  Google Scholar 

  17. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4(2): 87–94

    PubMed  CAS  Google Scholar 

  18. Miller MD, Margot NA, Hertogs K, et al. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001; 20: 1025–8

    Article  PubMed  CAS  Google Scholar 

  19. White KL, Margot NA, Wrin T, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002 Nov; 46(11): 3437–46

    Article  PubMed  CAS  Google Scholar 

  20. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002 Jun 14; 16(9): 1257–63

    Article  PubMed  CAS  Google Scholar 

  21. Squires K, Pozniak AL, Pierone Jr G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 Sep 2; 139 (5 Pt 1): 313–20

    PubMed  CAS  Google Scholar 

  22. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004 Mar 1; 189(5): 837–46

    Article  PubMed  CAS  Google Scholar 

  23. Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic analyses for detection of K65R or M184V in mixures with wild-type HIV-1 [abstract no. 130]. Antiviral Ther 2004; 9(4): S144

    Google Scholar 

  24. MColl DJ, Margot N, Cheng A, et al. Development of K65R versus thymidine analog-associated mutations (TAMs) in anti-retroviral-treated patients [abstract no. P206]. 6th International Congress of Drug Therapy in HIV Infection; 2002 Nov 17–21; Glasgow

  25. Margot NA, Isaacson E, McGowan I, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002 Jun 14; 16(9): 1227–35

    Article  PubMed  CAS  Google Scholar 

  26. Miller MD, Margot NA, MColl DJ, et al. Final 144 week resistance analysis for treatment-naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) [poster no. 5757]. 15th International AIDs Conference; 2004 Jul 11–16; Bangkok

  27. Winston A, Pozniak A, Mandalia S, et al. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004 Apr 9; 18(6): 949–51

    Article  PubMed  CAS  Google Scholar 

  28. Valer L, Martín-Carbonero L, Corral A, et al. Predictors of selection of K65R: tenofovir use and lack of TAMs [abstract no. 40]. Antiviral Ther 2004; 9(4): S46

    Google Scholar 

  29. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43(9): 595–612

    Article  PubMed  CAS  Google Scholar 

  30. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998 Sep; 42(9): 2380–4

    PubMed  CAS  Google Scholar 

  31. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001 Oct; 45(10): 2733–9

    Article  PubMed  CAS  Google Scholar 

  32. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004 Jan; 48(1): 124–9

    Article  PubMed  CAS  Google Scholar 

  33. European Agency for the Evaluation of Medicinal Products. Viread 245 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Sep 9]

  34. Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998 Jul; 42(7): 1568–73

    PubMed  CAS  Google Scholar 

  35. Van Gelder J, Deferme S, Annaert P, et al. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 2000 Dec; 28(12): 1394–6

    PubMed  Google Scholar 

  36. Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF [abstract no. A-1615]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago, 36

  37. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine, and tenofovir disoproxil fumarate for a once-daily antiretroviral regimen [abstract no. A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 14–17 Sep; Chicago, 36

  38. Kearney BP, Damle B, Plummer A, et al. Pharmacokinetic evaluation of tenofovir DF and enteric-coated didanosine [poster no. 9026]. 14th International AIDS Conference; 2002 Jul 7–12; Barcelona

  39. Kearney BP, Flaherty JF, Sayre JR, et al. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and lamivudine or didanosine [poster no. 337]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

  40. Flaherty JF, Kearney BP, Wolf JJ, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir [abstract no. 336 plus poster]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

  41. Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir [abstract no. A-1617 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago, 37

  42. Taburet A-M, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004 Jun; 48(6): 2091–6

    Article  PubMed  CAS  Google Scholar 

  43. Ray AS, Olson L, Fridland A. Role of purine nucleoside phos-phorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004 Apr; 48(4): 1089–95

    Article  PubMed  CAS  Google Scholar 

  44. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stauvudine in combination therapy in antiretroviral-naive patients. JAMA 2004 Jul 14; 292(2): 191–201

    Article  PubMed  CAS  Google Scholar 

  45. Cohen C, Skowron G, Nadler J, et al. Tenofovir DF: a final analysis of the open label extension phase from a 48 week, randomized, double blind, placebo controlled study in antiretroviral experienced patients [poster no. 226]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens

  46. Barrios A, Negredo E, Vilaró-Rodríguez J, et al. Safety and efficacy of a QD simplification regimen [abstract no. 566]. 11 th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

  47. Haberl A, Müller A, Mösch M, et al. Switch to tenofovir in patients with suppressed HI-viraemia [abstract no. 9.8/4]. 9th European AIDS Conference; 2003 Oct 25–29; Warsaw

  48. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure and occurence of resistance in naive patients receiving tenofovir, didanosine and efavirenz [abstract no. 156]. Antiviral Ther 2004; 9(4): S172

    Google Scholar 

  49. Farthing C, Khanlou H, Yeh V, et al. Early virologic failure in a pilot study evaluating the efficacy of one daily abacavir (ABC), lamivudine (3TC) and tenofovir DF (TDF) in treatment naive HIV-infected patients [oral presentation]. 2nd International AIDS Society Meeting; 2003 Jul 13–16; Paris

  50. Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis [abstract no. H-1722a]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

  51. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [abstract no. 51]. 11 th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

  52. Elion R, Cohen C, DeJesus E, et al. COL40263: resistance and efficacy of once-daily trizivir (TZV) and tenofovir DF (TDF) in antiretroviral naive subjects [abstract no. 53]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

  53. Ruane P, Luber A, Gaultier C, et al. Efficacy of trizivir (TZV) and tenofovir (TDF) as HAART for HIV infected patients with current or underlying reverse transcriptase (RT) resistance [poster no. 17286]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  54. Galindo MJ, López-Aldeguer J, Salavert M, et al. Efficacy and saftery of didanosine (ddl) and tenofovir (TDF) combination as NRTI backbone of highly active antiretroviral treatment (HAART) (24 wk preliminary results from Recover Study) [poster no. TuPeB4551]. 15th International AIDS Conference; 2004 Jul 11–14; Bangkok

  55. Moreno S, Perez Elias MJ, Terrón JA, et al. Virological outcome of tenofovir plus abacavir-based regimens in previously HIV suppressed patients (Recover Study) [poster no. TuPeB4549]. 15th International AIDS Conference; 2004 Jul 11–14; Bangkok

  56. Gallais H, Lazzarin A, Adam A, et al. The Viread expanded access program (EAP) in Europe/Australia: summary of the safety and efficacy of tenofovir disoproxil fumarate (TDF) in antiretroviral treatment (ART) experienced patients [poster no. 4552]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  57. Scott J, Behroozinia E, Quiros J, et al. Retrospective review of the use of tenofovir disoproxil fumarate (TDF) in two clinical practices [poster no. 4633]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  58. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B Virus. J Infect Dis 2004 Apr 1; 189(7): 1185–92

    Article  PubMed  CAS  Google Scholar 

  59. Louie M, Hogan C, Di Mascio M, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003 Mar 15; 187: 896–900

    Article  PubMed  CAS  Google Scholar 

  60. Negredo E, Moltó J, Muñoz-Moreno JA, et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther 2004 Jun; 9(3): 335–42

    PubMed  CAS  Google Scholar 

  61. Cheng A, Cheng SS, Wulfsohn M, et al. 2 year long term safety profile of tenofovir DF in treatment-experienced patients from randomized, double-blind, placebo-controlled clinical trials [abstract no. 7.3/7]. 9th European AIDS Conference; 2003 Oct 25–29; Warsaw

  62. Ruane R, Luber A, Gaultier C, et al. Improvement in dyslipidemias and continued virologic suppression after substitution of PIs or NNRTIs with tenofovir (TDF) among patients receiving HAART [poster no 4583]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  63. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004 Jul 2; 18(10): 1475–8

    Article  PubMed  Google Scholar 

  64. Lafeuillade A, Jolly P, Chadapaud S, et al. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens [letter]. J Acquir Immune Defic Syndr 2003 Aug 1; 33(4): 544–6

    Article  PubMed  CAS  Google Scholar 

  65. Staszewski S, Gallant JE, Pozniak AL, et al. Three-year analysis of the renal safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naive patients [poster no. 5917]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  66. Parish MA, Gallant JE, Moore R. Changes in renal function in patients treated with tenofovir DF vs nucleoside reverse transcriptase inhibitors [poster no. 751]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco

  67. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case control study. J Acquir Immune Defic Syndr 2004 Dec 1; 37(4): 1489–95

    Article  PubMed  CAS  Google Scholar 

  68. Scott J, Wolfe P, Quiros J, et al. Rare occurrence of renal impairment when retrospectively evaluating the use of TDF in two clinical practices [poster no. 4632]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  69. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003 Dec 15; 37(12): e174–6

    Article  PubMed  Google Scholar 

  70. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003 Aug 1; 37(3): e41–3

    Article  PubMed  CAS  Google Scholar 

  71. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002 Dec; 324(6): 342–4

    Article  PubMed  Google Scholar 

  72. Peyrière H, Reynes J, Rouanet I. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004 Mar 1; 35(3): 269–73

    Article  PubMed  Google Scholar 

  73. Cheng A, Barriere S, Coakley D, et al. Safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized, placebo-controlled trials [poster no. 227]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection; 2001 Oct 28–31; Athens

  74. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004 Sep 1; 37 Suppl. 1: S36–43

    Article  PubMed  CAS  Google Scholar 

  75. Harrigan PR, Miller MD, McKenna P, et al. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 2002 Apr; 46(4): 1067–72

    Article  PubMed  CAS  Google Scholar 

  76. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003 Oct 15; 37(8): 1112–8

    Article  PubMed  Google Scholar 

  77. Moyle G. Once-daily therapy: less is more. Int J STD AIDS 2003 Oct; 14 Suppl. 1: 1–5

    Article  PubMed  Google Scholar 

  78. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004 Mar 1; 38 Suppl. 2: S98–103

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Additional information

Various sections of the manuscript reviewed by: G. Beall, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA; S.L. Becker, Pacific Horizon Medical Group, San Francisco, California, USA; R. Colebunders, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; E. DeJesus, Infectious Disease Consultants, Altamonte Springs, Florida, USA; M.J. Pérez Elías, Clinical Research Department, Infectious Diseases Service, Ramon y Cajal Hospital, Madrid, Spain; C.R. Steinhart, Mercy Hospital, Miami, Florida, USA; D. Turner, AIDS Center, Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; A. Winston, National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia.

Data Selection

Sources: Medical literature published in any language since 1980 on tenofovir, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘tenofovir’. EMBASE search terms were ‘tenofovir’. AdisBase search terms were ‘tenofovir’. Searches were last updated 6 January 2005.

Selection: Studies in patients with HIV infection who received tenofovir disoproxil fumarate. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Tenofovir disoproxil fumarate, HIV infection, nucleotide reverse transcriptase inhibitors, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Reynolds, N.A. & Plosker, G.L. Tenofovir Disoproxil Fumarate. Drugs 65, 413–432 (2005). https://doi.org/10.2165/00003495-200565030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565030-00006

Keywords

Navigation